<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176134</url>
  </required_header>
  <id_info>
    <org_study_id>1986-018</org_study_id>
    <secondary_id>2016-003884-20</secondary_id>
    <secondary_id>MK-1986-018</secondary_id>
    <nct_id>NCT03176134</nct_id>
  </id_info>
  <brief_title>A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)</brief_title>
  <official_title>A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate&#xD;
      (MK-1986) compared with comparator antibacterial agent in participants from birth to less&#xD;
      than 12 years of age with acute bacterial skin and skin structure infections (ABSSSI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized (3:1) to receive tedizolid phosphate at a weight-based dose&#xD;
      ≤200 mg/day, intravenous (IV) and/or oral suspension for 6 to 10 days, or comparator IV&#xD;
      and/or oral per local standard of care for 10 to 14 days. The switch from IV to oral&#xD;
      administration can be made at any time based on 1) no worsening of the primary skin lesion,&#xD;
      2) last temperature &lt;37.7 °C, and 3) primary acute bacterial skin and skin structure&#xD;
      infection (ABSSSI) site has not worsened and at least 1 site has improved from Baseline. The&#xD;
      potential 4-day treatment extension will be based on clinical need as judged by the&#xD;
      investigator, considering the following criteria: 1) ≥40% reduction in primary lesion size,&#xD;
      2) reduction in pain, and 3) no new signs and symptoms and no complications attributable to&#xD;
      ABSSSI compared with Baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 adverse events (AEs)</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants with one or more AEs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants discontinuing from study therapy due to AEs</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants discontinued from the study due to an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with hematopoietic cytopenias</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>A standardized MedDRA query for hematopoietic cytopenia will be conducted. The percentage of participants with a hematopoietic cytopenia will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinical success</measure>
    <time_frame>Day 25</time_frame>
    <description>The investigator's assessment of clinical response will be conducted at the Test of Cure (TOC) visit, approximately 25 days after the first infusion. Clinical success is defined as 1) resolution or near-resolution of most signs and symptoms, 2) absence or near-resolution of signs of infection, and 3) no new signs, symptoms, or complications attributable to the infections (no further antibiotic therapy required for the primary lesion). The percentage of participants with clinical success will be reported.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Tedizolid phosphate 6 to &lt;12 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to &lt;50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to &lt;30 kg), by IV and/or oral suspension for 6 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Comparator: 6 to &lt;12 Years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Tedizolid phosphate 2 to &lt;6 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to &lt;50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to &lt;30 kg), by IV and/or oral suspension for 6 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Comparator: 2 to &lt;6 Years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Tedizolid phosphate 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to &lt;50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to &lt;30 kg), by IV and/or oral suspension for 6 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Comparator: 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Tedizolid phosphate Birth to &lt;28 Days Neonates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: Birth to &lt;28 Days (Term and preterm neonates)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedizolid phosphate</intervention_name>
    <description>Tedizolid phosphate IV solution or oral suspension</description>
    <arm_group_label>Cohort 1: Tedizolid phosphate 6 to &lt;12 Years</arm_group_label>
    <arm_group_label>Cohort 2: Tedizolid phosphate 2 to &lt;6 Years</arm_group_label>
    <arm_group_label>Cohort 3: Tedizolid phosphate 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_label>Cohort 4: Tedizolid phosphate Birth to &lt;28 Days Neonates</arm_group_label>
    <other_name>MK-1986</other_name>
    <other_name>TR-701 FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care</description>
    <arm_group_label>Cohort 1 Comparator: 6 to &lt;12 Years</arm_group_label>
    <arm_group_label>Cohort 2 Comparator: 2 to &lt;6 Years</arm_group_label>
    <arm_group_label>Cohort 3: Comparator: 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_label>Comparator: Birth to &lt;28 Days (Term and preterm neonates)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a parent/legally acceptable representative who is able to give documented informed&#xD;
             consent&#xD;
&#xD;
          -  Has ABSSSI, defined as ≥1 of the following: 1) cellulitis/erysipelas, 2) major&#xD;
             cutaneous abscess, or 3) wound infection&#xD;
&#xD;
          -  Local symptoms of ABSSSI that started within 14 days before study start&#xD;
&#xD;
          -  Suspected or documented Gram-positive bacterial infection&#xD;
&#xD;
          -  Body weight ≥3.2 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncomplicated skin and skin structure infection&#xD;
&#xD;
          -  ABSSSI due to or associated with disallowed etiology per protocol&#xD;
&#xD;
          -  Received antibacterial therapy for treatment of the current episode of ABSSSI except&#xD;
             1) &lt;24 hours of antibacterial therapy with a short-acting antibacterial drug, or 2)&#xD;
             response is considered to be failure (no improvement in signs and symptoms) after at&#xD;
             least 48 hours of therapy&#xD;
&#xD;
          -  Known bacteremia, severe sepsis, or septic shock&#xD;
&#xD;
          -  Significant or life-threatening condition, disease, or organ system condition&#xD;
&#xD;
          -  Recent history of opportunistic infections where the underlying cause of the infection&#xD;
             is still active, or is suspected to be at risk of opportunistic infection with unusual&#xD;
             pathogens&#xD;
&#xD;
          -  Received or is receiving treatment for active tuberculosis within 1 month of study&#xD;
             start&#xD;
&#xD;
          -  Known or suspected severe neutropenia&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive and has Cluster of Differentiation (CD) 4&#xD;
             cell count &lt;15% (HIV testing is not required for eligibility)&#xD;
&#xD;
          -  Renal impairment that requires renal filtration&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
&#xD;
          -  Cardiac or electrocardiogram (ECG) finding that would limit participation in the study&#xD;
&#xD;
          -  Received an investigational medicinal product (not approved) within 30 days before&#xD;
             study start&#xD;
&#xD;
          -  Investigational device present or removed within 30 days before study start&#xD;
&#xD;
          -  Previously treated with tedizolid phosphate&#xD;
&#xD;
          -  Contraindication, including hypersensitivity to tedizolid phosphate, other&#xD;
             oxazolidinones, or any component in the formulation&#xD;
&#xD;
          -  Contraindication, including hypersensitivity to all available comparator drugs&#xD;
&#xD;
          -  Wound infection and history of hypersensitivity to aztreonam adjunctive therapy or&#xD;
             metronidazole adjunctive therapy, if adjunctive therapy is required&#xD;
&#xD;
          -  Needs oral administration of methotrexate, topotecan, irinotecan, or rosuvastatin,&#xD;
             during administration of oral study drug (administration during the follow-up period,&#xD;
             ie, after the EOT visit, is allowed, as is administration during treatment with IV&#xD;
             drug)&#xD;
&#xD;
          -  Female who is pregnant or nursing or is of childbearing potential and not abstinent;&#xD;
             or male who is not abstinent&#xD;
&#xD;
          -  Use of monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective&#xD;
             serotonin reuptake inhibitors, or serotonin 5-hydroxytryptamine receptor agonists&#xD;
             (triptans)&#xD;
&#xD;
          -  Identified as having used illicit drugs (urine drug screening not required for entry)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 0118)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-966-8381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 0129)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-6285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan ( Site 0100)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital ( Site 0108)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital ( Site 0127)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center ( Site 0124)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>682-885-6740</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Texas Children's Hospital ( Site 0107)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU ( Site 0123)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pequeno Principe ( Site 0276)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+554133101356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0277)</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+558121224792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Sv. Nikolay Chudotvorets EOOD ( Site 0338)</name>
      <address>
        <city>Lom</city>
        <state>Montana</state>
        <zip>3600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359971660051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Deva Maria ( Site 0333)</name>
      <address>
        <city>Burgas</city>
        <zip>8127</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35956896282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT City Clinic Sv. Georgi EOOD ( Site 0334)</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359887397013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Stamen Iliev AD ( Site 0339)</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359887271111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr. Georgi Stranski EAD ( Site 0330)</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359886845270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Georgi ( Site 0332)</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35932602777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MBAL Medica Ruse EOOD ( Site 0336)</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359886353782</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev AD ( Site 0337)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359888209200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHATEM. N.I.Pirogov. EAD ( Site 0331)</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359888218961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC Evex Hospitals. ( Site 0601)</name>
      <address>
        <city>Batumi</city>
        <state>Ajaria</state>
        <zip>6010</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+995 599954015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical University G. Zhvania Pediatric Academic Clinic ( Site 0600)</name>
      <address>
        <city>Tiblisi</city>
        <state>Tbilisi</state>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00995577921221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC Evex Hospital ( Site 0602)</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00995599501990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC Evex Hospitals ( Site 0603)</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00995599546152</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haunersches Kinderspital ( Site 0480)</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+498951602811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Privada ( Site 0551)</name>
      <address>
        <city>Guatemala</city>
        <zip>01001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222537338</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Practice Mario Melgar ( Site 0552)</name>
      <address>
        <city>Guatemala</city>
        <zip>01009</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259010669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Practice Dra. Manrique ( Site 0553)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50257102451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital ( Site 0651)</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37129476495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liepaja Regional Hospital ( Site 0652)</name>
      <address>
        <city>Liepaja</city>
        <zip>3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37128335663</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas ( Site 0701)</name>
      <address>
        <city>Kaunas</city>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37068744843</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klaipedos Vaiku Ligonine ( Site 0700)</name>
      <address>
        <city>Klaipeda</city>
        <zip>92140</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37068698725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaiku ligonine VsI VUL Santaros kliniku filialas ( Site 0702)</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37068722516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 0231)</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525556440210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez ( Site 0227)</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525552289917x2331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil Fray Antonio Alcalde-pediatrics infectious diseases ( Site 0230)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523336138233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo-Pediatrics Department ( Site 0239)</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20259</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+524498907750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno Zakazny ( Site 0429)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48523255605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 0427)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48422516104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SZPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0431)</name>
      <address>
        <city>Lomianki</city>
        <state>Mazowieckie</state>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227657153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Childrens Clinical Emergency Hospital ( Site 0507)</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast</state>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79130100310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital ( Site 0511)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79036493912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children s Republican Clinical Hospital ( Site 0512)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79178783450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emmed Research Incorporating ( Site 0377)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre ( Site 0378)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Enhancing Care Foundation-DICRS ( Site 0381)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>27312054421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Uni Tip Fak Cocuk Saglıgı ve Hasta ABD ( Site 0353)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903223386060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0351)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903123114963</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osmangazi UTF ( Site 0357)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902222392979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi ( Site 0355)</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902124142000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sisli Hamide Etfal Egitim ve Arastirma Hastanesi ( Site 0358)</name>
      <address>
        <city>Istanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055803297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege UTF ( Site 0356)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323901427</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk Regional Children Consultative Policlinic ( Site 0868)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380677671524</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 0863)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380973830739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Children Clinical Hospital ( Site 0865)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+38342527868</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tedizolid</mesh_term>
    <mesh_term>Tedizolid phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

